

Endo International plc (ENDP)

\$4.17 (As of 05/05/20)

Price Target (6-12 Months): **\$4.50**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 05/28/19)

Prior Recommendation: Underperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

3-Hold

Zacks Style Scores:

VGM:B

Value: A

Growth: F

Momentum: A

Summary

Endo's efforts to revive its business are encouraging. Xiaflex's performance has been solid on higher demand in both Peyronie's disease and Dupuytren's contracture. The Sterile Injectables segment also boosted the top line, driven by continued strong growth in Vasostrict, Adrenalin and Aplisol. The pipeline progress has been impressive too. However, the decline in revenues due to competitive pressure in the generic pharmaceuticals segment is a concern. Moreover, Endo has been embroiled in various opioid litigations lately, which affected its share price. Earnings estimates for the first quarter are stable ahead of the quarterly release. Shares of the company have underperformed the industry in the past year.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$8.55 - \$1.97
20 Day Average Volume (sh)	4,320,066
Market Cap	\$956.7 M
YTD Price Change	-11.2%
Beta	1.61
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical - Drugs
Zacks Industry Rank	Top 5% (13 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	29.8%
Last Sales Surprise	5.3%
EPS F1 Est- 4 week change	-2.4%
Expected Report Date	05/07/2020
Earnings ESP	2.0%

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	704 E	718 E	731 E	756 E	2,830 E
2020	714 E	655 E	671 E	729 E	2,795 E
2019	720 A	700 A	729 A	765 A	2,914 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$0.52 E	\$0.55 E	\$0.57 E	\$0.63 E	\$2.23 E
2020	\$0.54 E	\$0.48 E	\$0.53 E	\$0.66 E	\$2.24 E
2019	\$0.53 A	\$0.52 A	\$0.60 A	\$0.74 A	\$2.38 A

*Quarterly figures may not add up to annual.

P/E TTM	1.7
P/E F1	1.9
PEG F1	NA
P/S TTM	0.3

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 05/05/2020. The reports text is as of 05/06/2020.

Overview

Endo International plc is a global specialty pharmaceutical company, which is focused on branded and generic pharmaceuticals. The company uses a differentiated operating model based on a lean and nimble structure, the rational allocation of capital, and an emphasis on high-value research and development (R&D) targets.

During the first quarter of 2019, Endo changed the names of its reportable segments.: (1) Branded Pharmaceuticals, (2) Sterile Injectables (3) Generic Pharmaceuticals (4) International Pharmaceuticals.


The Branded Pharmaceuticals segment accounted for 29.3% of total revenues in 2019. This segment consists of the company's legacy generics business together with the generic pharmaceuticals products obtained through the September 2015 acquisition of Par Pharmaceutical Holdings, Inc. (Par).

The Sterile Injectables accounted for approximately 36.5% of total revenues in 2019. This segment consists primarily of branded sterile injectable products such as Vasostrict, Adrenalin and Aplisol, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others.

The Generic Pharmaceuticals accounted for approximately 30.2% of total revenues in 2019. The portfolio includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics.

International Pharmaceuticals accounted for 4% of total revenues in 2019. The segment includes a variety of specialty pharmaceutical products sold outside the United States. This segment's key products serve growing therapeutic areas, including attention deficit hyperactivity disorder (ADHD), pain, women's health and oncology.

In 2019, total revenues came in at \$2.9 billion, down 1% from 2018.



Reasons To Buy:

- ▲ **Flagship Product, Xiaflex, Performing Well:** Xiaflex's performance has been solid driven by increased demand in both Peyronie's disease and Dupuytren's contracture. The company's efforts to market the drug for both the indications is yielding results. Per the company, Xiaflex is the first and only FDA-approved non-surgical treatment for PD.
- ▲ **Progress With CCH BLA:** In the third quarter of 2019, Endo submitted a Biologics License Application (BLA) to the FDA for collagenase clostridium histolyticum (CCH) to treat cellulite in the buttocks. The submission is based on positive results from two identical phase III RELEASE studies. The FDA accepted the BLA for review. The agency set a Prescription Drug User Fee Act (PDUFA) or target action date of Jul 6, 2020. A potential approval of CCH should boost Endo's top line, given its wide market potential.
- ▲ **Sterile Injectables Business Performing Well:** Strong performance from this business has boosted Endo's top line. Revenues are being driven by continued growth of Adrenalin and Vasostrict. The launch of the authorized generic of Invanz has further boosted sales. The business is poised to become Endo's core business.
- ▲ **Prioritizing R&D Efforts:** Endo has centralized and streamlined its global supply chain, quality and compliance organization in order to create a more cohesive and efficient structure to support both its generics and branded businesses. The company restructured its corporate functions as well as its branded and generic pharmaceutical R&D functions. Endo also discontinued approximately 85 generic products that were not significant contributors. A leaner structure will help the beleaguered company focus better on core areas.

We are impressed by Endo's growth-by-acquisition strategy. The company's efforts to prioritize its R&D projects bode well.

Reasons To Sell:

- ▼ **Share Price Performance:** Endo's stock has underperformed the industry in the past year. The company has been embroiled in various litigations related to opioid drugs of late, which has affected its share price. A couple of cases have been settled recently but the company still has many pending litigations related to opioid drugs.
- ▼ **Stiff Competition:** The company faces stiff competition from other generic drug manufacturers, brand name pharmaceutical companies through authorized generics, existing brand equivalents and manufacturers of therapeutically similar drugs. Major competitors in the generics market, including Teva Pharmaceutical, Mylan, Sandoz (a division of Novartis AG) and Amneal Pharmaceuticals, Inc. (Amneal) among others.
- ▼ **Slowdown in Generic Business:** Generics base business plummeted significantly due to the loss of marketing exclusivity for the first-to-file products- the generic version of Zetia (ezetimibe tablets) and the generic version of Seroquel XR (quetiapine extended-release (ER) tablets) both of which were launched in fourth-quarter 2016. Moreover, the base business is facing competitive pressures. Product discontinuances and pricing pressure from increased competition impacted the generic base business.

Endo's Generics base business continues to be under pressure given the challenging competitive landscape and pricing pressures.

Last Earnings Report

Endo's Earnings & Revenues Trump Estimates in Q4

Endo reported better-than-expected results for fourth-quarter 2019.

The company's earnings of 74 cents easily beat the Zacks Consensus Estimate of 57 cents in the reported quarter. However, earnings came in lower by a penny from the year-ago quarter's 75 cents.

Revenues came in at \$764.8 million in the quarter, surpassing the Zacks Consensus Estimate of \$726.7 million. The revenue figure, however, declined 3% from the year-ago quarter. This decrease primarily resulted from competitive pressure in the Generic Pharmaceuticals segment and the Established Products portfolio of the Branded Pharmaceuticals segment. However, this was partially offset by continued solid growth in the Sterile Injectables segment and the Specialty Products portfolio of the Branded Pharmaceuticals segment.

Quarterly Highlights

Endo has four reportable business segments — Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.

Branded Pharmaceuticals revenues were \$226 million, down from the year-ago quarter's \$230 million, due to the prevalent generic competition in the Established Products portfolio. Specialty Products revenues increased 15% to \$149 million on continued strong performance of Xiaflex. Sales of Xiaflex rose 27% to \$102 million, primarily attributable to demand growth in both Peyronie's Disease and Dupuytren's Contracture indications, driven by continued commercial execution and investment in promotional activities.

In November 2019, the FDA accepted the company's original Biologics License Application (BLA) for its Collagenase Clostridium Histolyticum (CCH) product, for the treatment of cellulite in the buttocks. The target action date for the BLA has been set for Jul 6, 2020.

Sterile Injectables revenues came in at \$285 million, up 10% year over year, aided by robust growth of Adrenalin and Vasostriect.

Generic Pharmaceuticals recorded sales of \$226 million in the fourth quarter, down 14% due to competitive pressure on commoditized generic products. Nevertheless, the contribution of certain recent product launches partially negated the decline.

International Pharmaceuticals revenues came in at \$29 million, marking a decline of 16% year on year.

2019 Results

Revenues came in at \$2.9 billion for full-year 2019, down 1% from 2018. Earnings per share for 2019 came in at \$2.38 compared with the prior year's \$2.89.

2020 Guidance

Endo expects revenues between \$2.72 billion and \$2.92 billion for 2020. The guidance assumes further erosion and competitive pressure for established brands. The company anticipates earnings from continuing operations to be \$2.15-\$2.40.

Quarter Ending **12/2019**

Report Date	Feb 26, 2020
Sales Surprise	5.25%
EPS Surprise	29.82%
Quarterly EPS	0.74
Annual EPS (TTM)	2.39

Recent News

Settles Opioid Investigation with Oklahoma — Jan 10

Endo announced that it has executed a settlement agreement with the state of Oklahoma related to a litigation that alleged the company's involvement in opioid abuse crisis in the state. The company has agreed to pay \$8.75 million to the state in connection with the settlement.

Launches Generic Version of Afinitor — Dec 10

Endo announced that one of its operating companies, Par Pharmaceutical (Par), launched the generic edition of Afinitor (everolimus) in 2.5 mg, 5 mg and 7.5 mg tablets.

BLA for Cellulite Treatment Accepted by FDA — Nov 19

Endo announced that the FDA has accepted the original Biologics License Application (BLA) for review of collagenase clostridium histolyticum (CCH) to treat cellulite in the buttocks.

Implements CEO Succession Plan – Nov 4

Endo announced that Paul V. Campanelli, the president and chief executive officer, plans to retire. Campanelli has been appointed the chairman of the board effective immediately and will also continue to serve as president and chief executive officer until his successor is appointed.

Culmination of Litigation Regarding FDA Compounding Policy- Sep 30

Endo announced the successful culmination of two litigations with the U.S. District Court for the District of Columbia regarding the unlawful compounding of vasopressin from bulk drug substances.

Valuation

Endo's shares are down 12% in the year-to-date period and down 47.8% over the trailing 12-month period. Stocks in the Zacks sub-industry and the Zacks Medical sector are down 9.9% and 3.6% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry is down 10.3% while the sector is up 1.5%.

The S&P 500 index is down 10.9% in the year-to-date period and 0.8% in the past year.

The stock is currently trading at 0.34X trailing 12-month sales per share, which compares to 2.36X for the Zacks sub-industry, 2.74X for the Zacks sector and 3.32X for the S&P 500 index.

Over the past five years, the stock has traded as high as 5.95X and as low as 0.18X, with a 5-year median of 0.74X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$4.5 price target reflects 0.37X trailing 12-month sales per share.

Industry Analysis Zacks Industry Rank: Top 5% (13 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
Dr. Reddys Laboratories Ltd (RDY)	Outperform	3
United Therapeutics Corporation (UTHR)	Outperform	2
Allergan plc (AGN)	Neutral	3
AMNEAL PHARMACEUTICALS, INC. (AMRX)	Neutral	3
Bausch Health Cos Inc. (BHC)	Neutral	3
Catalent, Inc. (CTLT)	Neutral	4
Jazz Pharmaceuticals PLC (JAZZ)	Neutral	3
Mallinckrodt public limited company (MNK)	Neutral	3

Industry Comparison Industry: Medical - Drugs				Industry Peers		
	ENDP	X Industry	S&P 500	BHC	MNK	RDY
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Outperform
Zacks Rank (Short Term)	3	-	-	3	3	3
VGM Score	B	-	-	B	A	A
Market Cap	956.72 M	99.50 M	19.65 B	5.91 B	236.62 M	8.39 B
# of Analysts	9	2	14	9	7	2
Dividend Yield	0.00%	0.00%	2.18%	0.00%	0.00%	0.52%
Value Score	A	-	-	A	A	C
Cash/Price	1.67	0.25	0.06	0.54	2.82	0.03
EV/EBITDA	9.29	-1.60	11.77	14.28	-12.63	15.68
PEG Ratio	NA	1.09	2.49	0.41	0.03	NA
Price/Book (P/B)	NA	3.08	2.64	5.21	0.12	4.03
Price/Cash Flow (P/CF)	0.80	9.67	10.48	1.60	0.14	18.76
P/E (F1)	1.84	15.79	19.10	4.35	0.51	27.89
Price/Sales (P/S)	0.33	5.45	2.00	0.69	0.08	3.45
Earnings Yield	53.85%	-17.43%	4.99%	22.94%	194.31%	3.60%
Debt/Equity	-9.70	0.02	0.74	21.71	2.50	0.01
Cash Flow (\$/share)	5.21	-0.49	7.01	10.49	20.20	2.70
Growth Score	F	-	-	C	B	A
Hist. EPS Growth (3-5 yrs)	-14.42%	3.65%	10.87%	-19.61%	2.51%	-0.76%
Proj. EPS Growth (F1/F0)	-5.79%	17.25%	-9.07%	-13.02%	-38.55%	19.41%
Curr. Cash Flow Growth	-15.98%	4.73%	5.88%	-14.18%	10.71%	29.21%
Hist. Cash Flow Growth (3-5 yrs)	2.66%	6.05%	8.55%	-4.00%	10.87%	-0.91%
Current Ratio	1.77	3.03	1.24	1.12	1.46	1.81
Debt/Capital	NA%	6.72%	44.07%	95.60%	71.43%	0.81%
Net Margin	-14.50%	-107.81%	11.00%	-20.79%	-39.56%	9.62%
Return on Equity	-84.43%	-62.63%	16.39%	68.06%	29.14%	18.08%
Sales/Assets	0.30	0.32	0.55	0.26	0.30	0.75
Proj. Sales Growth (F1/F0)	-4.09%	0.00%	-2.17%	-2.80%	-14.72%	6.07%
Momentum Score	A	-	-	D	C	B
Daily Price Chg	-3.59%	0.00%	0.74%	0.60%	-14.85%	-2.11%
1 Week Price Chg	7.52%	0.00%	0.53%	1.42%	-6.46%	-2.49%
4 Week Price Chg	29.35%	15.90%	6.47%	13.00%	34.45%	13.52%
12 Week Price Chg	-33.68%	-13.53%	-20.68%	-40.43%	-44.47%	13.68%
52 Week Price Chg	-47.35%	-32.38%	-10.95%	-34.17%	-82.56%	19.56%
20 Day Average Volume	4,320,066	167,457	2,492,530	4,978,198	7,032,955	244,326
(F1) EPS Est 1 week change	1.56%	0.00%	0.00%	-2.25%	-3.41%	0.00%
(F1) EPS Est 4 week change	-2.42%	0.00%	-7.39%	-7.05%	-15.86%	-6.20%
(F1) EPS Est 12 week change	-1.79%	-1.00%	-14.21%	-14.10%	-20.28%	-4.22%
(Q1) EPS Est Mthly Chg	-7.97%	0.00%	-13.52%	-17.05%	-22.99%	NA

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	A
Growth Score	F
Momentum Score	A
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.